JAC Advance Access published online on October 31, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl444
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 AVI BioPharma, Inc., Corvallis, OR, USA
* To whom correspondence should be addressed. Objectives: Phosphorodiamidate morpholino oligomers (PMOs) are DNA analogues that inhibit translation by an antisense mechanism. Membrane-penetrating peptides attached to PMOs increase PMO efficacy by enhancing penetration through bacterial membranes. The objectives of these experiments are to demonstrate gene-specific efficacy and establish a dose-response relationship of a peptide-PMO conjugate. Methods: An 11-base PMO (AcpP) targeted at acpP (an essential gene) of Escherichia coli was synthesized and conjugated with the cell-penetrating peptide RFFRFFRFFRXB (X is 6-aminohexanoic acid and B is Results: Twelve hours after a single treatment, 30 µg of AcpP peptide-PMO or 3 mg of AcpP PMO reduced bacteraemia by 3 orders of magnitude compared with treatment with water. Neither scrambled base sequence PMO controls nor 30 µg of ampicillin reduced bacteraemia. Two treatments with 30 µg of AcpP peptide-PMO reduced cfu significantly more than four treatments with 15 µg at 15 min, 4, 8 and 12 h. Mice treated with doses of AcpP peptide-PMO >30 µg showed further reductions in plasma cfu. Survival 48 h after treatment with 2 x 30 µg (3 mg/kg) of AcpP peptide-PMO or 2 x 3 mg (300 mg/kg) of AcpP PMO was 100%, compared with 20% for mice treated with water or scrambled base sequence PMO controls. However, survival was reduced to 75% and 0% for mice treated with 2 x 300 µg and 2 x 1 mg of AcpP peptide-PMO, respectively. A conjugate made from the D-isomeric form of each amino acid was less effective than the L-amino acid equivalent, and required 2 x 300 µg treatments for significant reduction in bacteria and survival. Mice infected with LT1 and treated with AcpP peptide-PMO did not survive and had the same amount of bacteria in the blood as mice treated with water, whereas those treated with 2 x 100 µg of AcpPmut4 peptide-PMO (complementary to the mutated allele) survived, and had a 3 orders of magnitude reduction in bacteria in the blood at 24 h post-infection. Conclusions: Both AcpP peptide-PMO and AcpP PMO significantly reduced bacteraemia and promoted survival of mice infected with E. coli W3110. The conjugate was about 50-100 times more potent than the PMO without attached peptide. The L-isomeric peptide-PMO was 10 times more potent than the D-isomeric equivalent. The conjugate apparently was toxic at doses
Received August 1, 2006
Revised September 19, 2006
Accepted October 8, 2006
Original article
Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli
Lucas D. Tilley 1, Brett L. Mellbye 1, Susan E. Puckett 2, Patrick. L. Iversen 1, and Bruce L. Geller 3 *
2 The Department of Microbiology, Oregon State University, Corvallis, OR, USA
3 AVI BioPharma, Inc., Corvallis, OR, USA; The Department of Microbiology, Oregon State University, Corvallis, OR, USA
Bruce L. Geller, E-mail: gellerb{at}orst.edu
Abstract 
-alanine). Mice were infected by intraperitoneal (ip) injection with K-12 E. coli W3110, and treated ip at 15 min and 12 h post-infection with various amounts of AcpP peptide-PMO conjugate, AcpP PMO without attached peptide, scrambled base sequence PMOs or ampicillin. A strain (LT1) of E. coli was constructed by replacing acpP with an allele that has four wobble base substitutions in the region targeted by the PMO.
2 x 300 µg/mouse (30 mg/kg). PMOs produced a sequence-specific antibiotic effect and the conjugate had a therapeutic index (toxic dose/effective dose) approximately equal to 10 in a mouse model of infection.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. L. Mellbye, D. D. Weller, J. N. Hassinger, M. D. Reeves, C. E. Lovejoy, P. L. Iversen, and B. L. Geller Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo J. Antimicrob. Chemother., November 1, 2009; (2009) dkp392v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. C. Soler Bistue, F. A. Martin, N. Vozza, H. Ha, J. C. Joaquin, A. Zorreguieta, and M. E. Tolmasky Inhibition of aac(6')-Ib-mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria PNAS, August 11, 2009; 106(32): 13230 - 13235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Meng, H. Wang, Z. Hou, T. Chen, J. Fu, X. Ma, G. He, X. Xue, M. Jia, and X. Luo Novel Anion Liposome-Encapsulated Antisense Oligonucleotide Restores Susceptibility of Methicillin-Resistant Staphylococcus aureus and Rescues Mice from Lethal Sepsis by Targeting mecA Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2871 - 2878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shen, J.-h. Ko, G. Xiao, D. Wesolowski, G. Shan, B. Geller, M. Izadjoo, and S. Altman Inactivation of expression of several genes in a variety of bacterial species by EGS technology PNAS, May 19, 2009; 106(20): 8163 - 8168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Woodford, D. W. Wareham, and on behalf of the UK Antibacterial Antisense Study Tackling antibiotic resistance: a dose of common antisense? J. Antimicrob. Chemother., February 1, 2009; 63(2): 225 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Mellbye, S. E. Puckett, L. D. Tilley, P. L. Iversen, and B. L. Geller Variations in Amino Acid Composition of Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Affect Potency against Escherichia coli In Vitro and In Vivo Antimicrob. Agents Chemother., February 1, 2009; 53(2): 525 - 530. [Abstract] [Full Text] [PDF]
|
|